middle.news
Chimeric Therapeutics Secures $8.4M Funding, Eyes April EGM for Key Approvals
9:22am on Wednesday 25th of February, 2026 AEDT
•
Healthcare
Read Story
Chimeric Therapeutics Secures $8.4M Funding, Eyes April EGM for Key Approvals
9:22am on Wednesday 25th of February, 2026 AEDT
Key Points
First tranche of $2.3M placement settled in December 2025/January 2026
April 2026 EGM to approve $2.1M second tranche, $4M convertible note, and share consolidation
Funding fully supports CHM CDH17 CAR-T Phase 1 clinical trial through to completion
Strategic cost reduction and governance changes underway, including new Non-Executive Chair
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
CHIMERIC THERAPEUTICS (ASX:CHM)
OPEN ARTICLE